Compare Quantumscape Corp (QS) vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quantumscape Corp vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) — how do they compare? Quantumscape Corp trades at $4.58 (market cap $2.82B), while Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.68 (market cap $58.74B). The key difference: Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) is far larger — about 20.8× Quantumscape Corp's market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays a 3.33% dividend while Quantumscape Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quantumscape Corp for 37 Days and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 1 Days on average.
| QS | TAK | |
|---|---|---|
Market Cap | $2.82B | $58.74B |
Volume | 21,878,246 | 3,110,994 |
Sector | Consumer Cyclical | Health |
52-Week High | $18.44 | $19.05 |
52-Week Low | $4.52 | $13.23 |
Typical Hold Time | 37 Days | 1 Days |
Enterprise Value | $2.03B | $86.65B |
Dividend Yield | — | 3.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QuantumScape (QS) trades at $4.58, up 1.33% with bearish technical signals and negative profitability metrics. The company remains pre-revenue with significant cash burn, though recent earnings beat expectations. Analyst consensus shows 72.7% hold ratings with a $10.35 price target, while insider selling and delayed commercialization timelines create headwinds.
QS faces substantial execution risk with commercialization not expected until 2029, but maintains automotive partnerships and pilot production progress. The stock trades near 52-week lows, offering potential upside to analyst targets if technology milestones are achieved, though high cash burn and competitive threats remain key concerns.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quantumscape Corp
QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles. It developed anode-less cell design, which delivers high energy density while lowering material costs and simplifying manufacturing.
Read more on QS →About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →
